(CCJ) Cameco - Overview
Stock: Uranium, Fuel Services, Nuclear Technology
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.20% |
| Yield on Cost 5y | 1.18% |
| Yield CAGR 5y | 28.54% |
| Payout Consistency | 94.4% |
| Payout Ratio | 17.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 51.2% |
| Relative Tail Risk | -5.69% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.79 |
| Alpha | 108.85 |
| Character TTM | |
|---|---|
| Beta | 1.141 |
| Beta Downside | 1.024 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.01% |
| CAGR/Max DD | 1.46 |
Description: CCJ Cameco January 28, 2026
Cameco Corp (NYSE: CCJ) is a vertically integrated uranium producer headquartered in Saskatoon, Canada. Its operations are organized into three segments: Uranium (exploration, mining, milling, and sales of U₃O₈ concentrate), Fuel Services (conversion, enrichment, and fabrication of nuclear fuel), and Westinghouse (design, OEM, and aftermarket services for commercial nuclear reactors).
In the most recent fiscal quarter (Q4 2023), Cameco reported 1.1 million pounds of U₃O₈ production, a 4 % increase year-over-year, while its cash flow from operations rose to $1.2 billion, driven by a 30 % jump in spot uranium prices to ≈ $55 per lb. The company’s forward-looking guidance assumes uranium prices averaging $55-$60 per lb in 2024, a range that aligns with the International Atomic Energy Agency’s (IAEA) forecast of a 6-8 % rise in global nuclear electricity generation demand.
Key economic drivers for Cameco include the tightening uranium supply-demand balance as legacy mines close, the resurgence of nuclear power in Europe’s net-zero strategies, and the U.S. Department of Energy’s $2.5 billion loan program for domestic enrichment capacity. A material uncertainty remains the timing of new reactor construction in Asia, which could materially affect long-term demand projections.
For a deeper quantitative analysis, see ValueRay’s detailed model.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 526.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 6.83 > 1.0 |
| NWC/Revenue: 36.28% < 20% (prev 35.41%; Δ 0.87% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.26b > Net Income 526.0m |
| Net Debt (228.5m) to EBITDA (1.07b): 0.21 < 3 |
| Current Ratio: 2.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (435.4m) vs 12m ago -0.02% < -2% |
| Gross Margin: 29.05% > 18% (prev 0.24%; Δ 2881 % > 0.5%) |
| Asset Turnover: 36.41% > 50% (prev 30.11%; Δ 6.31% > 0%) |
| Interest Coverage Ratio: 9.54 > 6 (EBITDA TTM 1.07b / Interest Expense TTM 78.0m) |
Altman Z'' 4.87
| A: 0.13 (Total Current Assets 1.89b - Total Current Liabilities 631.4m) / Total Assets 9.74b |
| B: 0.36 (Retained Earnings 3.49b / Total Assets 9.74b) |
| C: 0.08 (EBIT TTM 744.0m / Avg Total Assets 9.51b) |
| D: 2.22 (Book Value of Equity 6.57b / Total Liabilities 2.96b) |
| Altman-Z'' Score: 4.87 = AA |
Beneish M -3.53
| DSRI: 0.49 (Receivables 190.9m/312.2m, Revenue 3.46b/2.80b) |
| GMI: 0.82 (GM 29.05% / 23.81%) |
| AQI: 0.97 (AQ_t 0.47 / AQ_t-1 0.48) |
| SGI: 1.24 (Revenue 3.46b / 2.80b) |
| TATA: -0.08 (NI 526.0m - CFO 1.26b) / TA 9.74b) |
| Beneish M-Score: -3.53 (Cap -4..+1) = AAA |
What is the price of CCJ shares?
Over the past week, the price has changed by -5.47%, over one month by +7.44%, over three months by +20.81% and over the past year by +126.07%.
Is CCJ a buy, sell or hold?
- StrongBuy: 10
- Buy: 9
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CCJ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 121 | 6.5% |
| Analysts Target Price | 121 | 6.5% |
| ValueRay Target Price | 174.7 | 53.8% |
CCJ Fundamental Data Overview February 07, 2026
P/E Trailing = 122.7865
P/E Forward = 74.6269
P/S = 13.7745
P/B = 10.0574
P/EG = 3.33
Revenue TTM = 3.46b CAD
EBIT TTM = 744.0m CAD
EBITDA TTM = 1.07b CAD
Long Term Debt = 996.2m CAD (from longTermDebt, last quarter)
Short Term Debt = 289.2m CAD (from shortTermDebt, last fiscal year)
Debt = 1.01b CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = 228.5m CAD (from netDebt column, last quarter)
Enterprise Value = 65.40b CAD (65.17b + Debt 1.01b - CCE 778.7m)
Interest Coverage Ratio = 9.54 (Ebit TTM 744.0m / Interest Expense TTM 78.0m)
EV/FCF = 67.24x (Enterprise Value 65.40b / FCF TTM 972.5m)
FCF Yield = 1.49% (FCF TTM 972.5m / Enterprise Value 65.40b)
FCF Margin = 28.07% (FCF TTM 972.5m / Revenue TTM 3.46b)
Net Margin = 15.18% (Net Income TTM 526.0m / Revenue TTM 3.46b)
Gross Margin = 29.05% ((Revenue TTM 3.46b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 37.32% (prev 29.31%)
Tobins Q-Ratio = 6.71 (Enterprise Value 65.40b / Total Assets 9.74b)
Interest Expense / Debt = 1.76% (Interest Expense 17.8m / Debt 1.01b)
Taxrate = 33.06% (84.9m / 256.7m)
NOPAT = 498.0m (EBIT 744.0m * (1 - 33.06%))
Current Ratio = 2.99 (Total Current Assets 1.89b / Total Current Liabilities 631.4m)
Debt / Equity = 0.15 (Debt 1.01b / totalStockholderEquity, last quarter 6.78b)
Debt / EBITDA = 0.21 (Net Debt 228.5m / EBITDA 1.07b)
Debt / FCF = 0.23 (Net Debt 228.5m / FCF TTM 972.5m)
Total Stockholder Equity = 6.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.53% (Net Income 526.0m / Total Assets 9.74b)
RoE = 7.98% (Net Income TTM 526.0m / Total Stockholder Equity 6.59b)
RoCE = 9.80% (EBIT 744.0m / Capital Employed (Equity 6.59b + L.T.Debt 996.2m))
RoIC = 6.50% (NOPAT 498.0m / Invested Capital 7.66b)
WACC = 9.98% (E(65.17b)/V(66.17b) * Re(10.12%) + D(1.01b)/V(66.17b) * Rd(1.76%) * (1-Tc(0.33)))
Discount Rate = 10.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.14%
[DCF Debug] Terminal Value 75.09% ; FCFF base≈700.8m ; Y1≈864.5m ; Y5≈1.47b
Fair Price DCF = 40.12 (EV 17.70b - Net Debt 228.5m = Equity 17.47b / Shares 435.4m; r=9.98% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 22.75 | EPS CAGR: -23.29% | SUE: -1.68 | # QB: 0
Revenue Correlation: 73.46 | Revenue CAGR: 7.75% | SUE: -0.58 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.46 | Chg30d=+0.066 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=1.94 | Chg30d=-0.028 | Revisions Net=-1 | Growth EPS=+39.0% | Growth Revenue=+8.1%